动态风险分层预测未行放射性碘残余消融治疗的分化型甲状腺癌患者复发
该历史队列研究纳入357例接受甲状腺腺叶切除或全甲状腺切除、未行放射性碘残余消融的分化型甲状腺癌患者,按动态风险分层分为极好、不确定、生化不完全和结构不完全四组。中位随访8.6年,3.6%出现结构性复发;生化不完全组HR=20.8、结构不完全组HR=243.3,均显著高于极好组。TNM分期和ATA初始风险分类未能有效预测复发。
要点
- 动态风险分层四组间无病生存率存在显著差异(p < 0.001)。
- 生化不完全组复发/持续疾病风险显著高于极好组(HR=20.8,p < 0.001)。
- 结构不完全组复发/持续疾病风险显著高于极好组(HR=243.3,p < 0.001)。
核心结论
- 新动态风险分层系统可有效预测未行放射性碘残余消融、接受腺叶切除或全甲状腺切除的分化型甲状腺癌患者的复发/持续疾病风险。
研究设计与样本
- 历史队列研究,纳入357例接受腺叶切除或全甲状腺切除、未行放射性碘残余消融治疗的分化型甲状腺癌患者。
- 根据动态风险分层系统将患者对初始治疗的反应分为极好、不确定、生化不完全和结构不完全四组。
主要发现
- 中位随访8.6年,3.6%患者出现结构性复发/持续疾病。
- 治疗反应分布为极好71.7%、不确定18.5%、生化不完全8.4%、结构不完全1.4%。
- 动态风险分层各组间无病生存率存在显著差异(p < 0.001)。
- 生化不完全组复发/持续疾病风险显著高于极好组(HR=20.8,p < 0.001)。
- 结构不完全组复发/持续疾病风险显著高于极好组(HR=243.3,p < 0.001)。
关键数值与推荐
- TNM分期系统和美国甲状腺协会初始风险分类未能有效预测分化型甲状腺癌复发。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Increased incidence of small differentiated thyroid cancer (DTC) has emphasized the need for risk stratification and individualized disease management for these low risk DTCs. The aim of this study was to validate a new dynamic risk stratification (DRS) system for the prediction of structural recurrent/persistent disease in patients with DTC treated without radioactive iodine (RAI) remnant ablation therapy. METHODS: This historical cohort study included 357 patients with DTC treated with lobectomy or total thyroidectomy without RAI therapy. We stratified patient response to initial treatment as excellent, indeterminate, biochemical incomplete, and structural incomplete according to the DRS system. RESULTS: During a median follow-up of 8.6 years, 3.6% patients had structural recurrent DTC. The response was excellent in 71.7% patients, indeterminate in 18.5%, biochemical incomplete in 8.4%, and structural incomplete in 1.4%. There were significant differences in DFS among the DRS groups (p < 0.001). The hazard ratio (HR) of recurrent/persistent disease was significantly higher in the biochemical incomplete group (HR = 20.8, p < 0.001) and structural incomplete group (HR = 243.3, p < 0.001) compared with the excellent group. However, the Tumor Node Metastasis staging system and the American Thyroid Association initial risk classification did not effectively predict recurrence of DTC. CONCLUSIONS: The new DRS system was effective for predicting risk of recurrent/persistent disease in patients with DTC who underwent lobectomy or total thyroidectomy without RAI remnant ablation.
引用
- Park S, Kim WG, Song E, et al. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy. Thyroid. 2016. PMID: 27869547. doi:10.1089/thy.2016.0477
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。